Pattern of Buprenorphine Treatment Retention Among Youth Aged 10 to 18 Years-US, 2015 to 2021.
作者信息
Connolly Sarah, Terranella Andrew, Guy Gery P, Mikosz Christina A
机构信息
Epidemic Intelligence Service, Division of Overdose Prevention, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Overdose Prevention, National Center for Injury Prevention and Control, US Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
JAMA Pediatr. 2024 Sep 1;178(9):940-942. doi: 10.1001/jamapediatrics.2024.2502.
Abstract
摘要
相似文献
1
Pattern of Buprenorphine Treatment Retention Among Youth Aged 10 to 18 Years-US, 2015 to 2021.2015年至2021年美国10至18岁青少年丁丙诺啡治疗保留模式
JAMA Pediatr. 2024 Sep 1;178(9):940-942. doi: 10.1001/jamapediatrics.2024.2502.
2
Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder.阿片类药物使用障碍布比卡因治疗发作的平均日剂量轨迹。
Subst Use Addctn J. 2024 Oct;45(4):727-735. doi: 10.1177/29767342241263161. Epub 2024 Jul 28.
3
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.美沙酮预处理戒断的芬太尼住院患者。
JAMA Netw Open. 2024 Sep 3;7(9):e2435895. doi: 10.1001/jamanetworkopen.2024.35895.
4
Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.美沙酮与丁丙诺啡治疗阿片类物质使用障碍的有效性：前瞻性队列研究数据的二次分析
BMJ Open. 2025 Jun 17;15(6):e095645. doi: 10.1136/bmjopen-2024-095645.
5
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.经改良的 7 天缓释注射用丁丙诺啡治疗轻至中度阿片类药物戒断症状。
JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702.
6
Differences in prescribing patterns of opioid dependence drugs among patients with primary alcohol use problems and opioid use disorders within New York State by social determinant factors, 2005-2018.2005 - 2018年纽约州社会决定因素对原发性酒精使用问题患者与阿片类药物使用障碍患者阿片类药物依赖药物处方模式的影响差异
J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102258. doi: 10.1016/j.japh.2024.102258. Epub 2024 Sep 27.
7
Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form.丁丙诺啡：从黏膜剂型到缓释皮下注射剂型桥接的 2 例青少年病例报告。
J Addict Dis. 2024 Oct-Dec;42(4):426-431. doi: 10.1080/10550887.2023.2251366. Epub 2024 Jan 25.
8
Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.为使用芬太尼的人群进行门诊低剂量丁丙诺啡起始治疗。
JAMA Netw Open. 2025 Jan 2;8(1):e2456253. doi: 10.1001/jamanetworkopen.2024.56253.
9
Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization.丁丙诺啡日剂量与紧急医疗保健利用的关联。
JAMA Netw Open. 2024 Sep 3;7(9):e2435478. doi: 10.1001/jamanetworkopen.2024.35478.
10
10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder.丁丙诺啡综合治疗模式用于阿片类物质使用障碍的10年留存率
J Addict Dis. 2025 Jan-Mar;43(1):44-51. doi: 10.1080/10550887.2024.2315366. Epub 2024 Feb 24.
引用本文的文献
1
A Global Perspective on Incidence and Regional Trends of Opioid Use Disorders From 1990 to 2021.1990年至2021年阿片类物质使用障碍发病率及区域趋势的全球视角
Psychiatry Investig. 2025 Jun;22(6):668-677. doi: 10.30773/pi.2025.0039. Epub 2025 Jun 16.
Zotero 插件